Skip to main content
. Author manuscript; available in PMC: 2023 Feb 1.
Published in final edited form as: Nature. 2021 Dec 23;602(7898):664–670. doi: 10.1038/s41586-021-04386-2

Fig. 3. Neutralization of Omicron SARS-CoV-2 VSV pseudovirus by clinical-stage mAbs.

Fig. 3.

a, RBD sequence of SARS-CoV-2 Wuhan-Hu-1 with highlighted footprints of ACE2 (light blue) and mAbs (colored according to the RBD antigenic site recognized). Omicron RBD is also shown, and amino acid substitutions are boxed. b, Neutralization of SARS-CoV-2 VSV pseudoviruses displaying Wuhan-Hu-1 (white) or Omicron (colored as in Fig. 4b) S proteins by clinical-stage mAbs. Data are representative of one independent experiment out of two. Shown is the mean of 2 technical replicates. c, Geometric mean IC50 values for Omicron (colored as in Fig. 4b) and Wuhan-Hu-1 (white) (top panel), and geometric mean fold change (bottom panel). Vero E6 used as target cells. Shown in blue (right) is neutralization of authentic virus by sotrovimab (WA1/2020 versus hCoV-19/USA/WI-WSLH-221686/2021). Non-neutralizing IC50 titers and fold change were set to 104 and 103, respectively. Orange dots for sotrovimab indicate neutralization of Omicron VSV pseudovirus carrying R346K. Data are representative of n = 2 biologically independent experiments for most mAbs, for sotrovimab against Omicron VSV n=6 and for Omicron authentic virus n=3.